Abstract: The present invention provides compounds of the formula as fibroblast growth factor receptor 3 (FGFR3) inhibitors for the treatment of e.g. cancer systemic sclerosis fibrosis pulmonary fibrosis achondroplasia thanatophoric dysplasia severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) and muenke syndrome. Preferred compounds are e.g. pyrazolo[1 5 a]pyridine and imidazo[1 2 a]pyridine derivatives.
| # | Name | Date |
|---|---|---|
| 1 | 202517020234-STATEMENT OF UNDERTAKING (FORM 3) [06-03-2025(online)].pdf | 2025-03-06 |
| 2 | 202517020234-PRIORITY DOCUMENTS [06-03-2025(online)].pdf | 2025-03-06 |
| 3 | 202517020234-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [06-03-2025(online)].pdf | 2025-03-06 |
| 4 | 202517020234-FORM 1 [06-03-2025(online)].pdf | 2025-03-06 |
| 5 | 202517020234-DECLARATION OF INVENTORSHIP (FORM 5) [06-03-2025(online)].pdf | 2025-03-06 |
| 6 | 202517020234-COMPLETE SPECIFICATION [06-03-2025(online)].pdf | 2025-03-06 |
| 7 | 202517020234-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [06-03-2025(online)].pdf | 2025-03-06 |
| 8 | 202517020234-MARKED COPIES OF AMENDEMENTS [12-03-2025(online)].pdf | 2025-03-12 |
| 9 | 202517020234-FORM 18 [12-03-2025(online)].pdf | 2025-03-12 |
| 10 | 202517020234-FORM 13 [12-03-2025(online)].pdf | 2025-03-12 |
| 11 | 202517020234-AMMENDED DOCUMENTS [12-03-2025(online)].pdf | 2025-03-12 |
| 12 | 202517020234-FORM-26 [17-03-2025(online)].pdf | 2025-03-17 |
| 13 | 202517020234-FORM 3 [13-05-2025(online)].pdf | 2025-05-13 |
| 14 | 202517020234-Proof of Right [21-05-2025(online)].pdf | 2025-05-21 |